Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
28.98
+0.44 (1.54%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.15 - 29.25
52 week 12.27 - 38.10
Open 28.45
Vol / Avg. 136,970.00/237,158.00
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -6.58
Shares 38.30M
Beta     -
Inst. own 54%
Aug 10, 2015
Q2 2015 Coherus BioSciences Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Coherus BioSciences Inc Earnings Release
Jun 3, 2015
Coherus Biosciences Inc at Jefferies 2015 Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -859.80% -280.26%
Operating margin -857.78% -207.94%
EBITD margin - -205.77%
Return on average assets -117.60% -74.30%
Return on average equity -349.73% -
Employees 95 -
CDP Score - -

Address

201 Redwood Shores Pkwy Ste 200
REDWOOD CITY, CA 94065-1181
United States - Map
+1-650-6493530 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company's clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF), and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company's product pipeline includes anti-TNF product candidate, CHS-0214, an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials, and anti-TNF product candidate, CHS-1420, an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate, CHS-1701, a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.

Officers and directors

Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Christos Richards Director
Age: 57
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 58
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Ali J. Satvat Independent Director
Age: 37
Bio & Compensation  - Reuters